



Publikationsliste (Stand: 04/2023)

**Prof. Dr. med. Marcus Hentrich,
Chefarzt Innere Medizin III – Hämatologie und Onkologie**

Originalarbeiten, Fallberichte und Reviews

1. Hentrich M, Böll B, Teschner D, Panse J, Schmitt T, Naendrup JH, Schmidt-Hieber M, Neitz J, Fiegler E, Schalk E. Impact of the insertion site of central venous catheters on central venous catheter-related bloodstream infections in patients with cancer: results from a large prospective registry. *Infection*. 2023 Apr 4. doi: 10.1007/s15010-023-02029-4. Online ahead of print. PMID: 37016194
2. Giesen N, Busch E, Schalk E, Beutel G, Rührich MM, Hentrich M, Hertenstein B, Hirsch HH, Karthaus M, Khodamoradi Y, Koehler P, Krüger W, Koldehoff M, Krause R, Mellinshoff SC, Penack O, Sandherr M, Seggewiss-Bernhardt R, Spiekermann K, Sprute R, Stemler J, Weissinger F, Wörmann B, Wolf HH, Cornely OA, Rieger CT, von Lilienfeld-Toal M. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. *Eur J Cancer*. 2023 Mar;181:102-118. PMID: 36652889
3. Berdel AF, Koch R, Gerss J, Hentrich M, Peceny R, Bartscht T, Steffen B, Bischoff M, Spiekermann K, Angenendt L, Mikesch JH, Kewitz T, Butterfass-Bahloul T, Serve H, Lenz G, Berdel WE, Krug U, Schliemann C., et al. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy *Ann Hematol* 2023 Jan;102(1):63-72. PMID 36399194
4. Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebbersold DM, Putora PM, Berthold DR, Zihler D, Zengerling F, Dieing A, Mueller AC, Schaer C, Biaggi C, Gillissen S, Cathomas R. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*. 2022 Nov;23(11):1441-50. PMID: 36228644
5. Hoffmann C, Hentrich M, Tiemann M, Rosenwald A, Weber F, Willenbacher W, Hübel K. Recent advances in Castleman disease. *Oncol Res Treat*. 2022;45(11):693-704. PMID: 36219975
6. Schalk E, Schmitt T, Panse J, Fiegler E, Naendrup JH, Schmidt-Hieber M, Böll B, Hentrich M, Teschner D, Mougialakos D. Central venous catheter-related bloodstream infections in patients with haematological malignancies during the SARS-CoV-2 pandemic. *Br J Haematol*. 2022;199(4):e16-e20. PMID: 36017820
7. Migaud P, Müller M, Arastéh K, Hentrich M, Stocker H. Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders. *Ann Hematol*. 2022 Oct;101(10):2281-7. doi: 10.1007/s00277-022-04944-2. Epub 2022 Aug 19. PMID: 35982337
8. Panse J, Tölle D, Fiegler E, Naendrup JH, Schmidt-Hieber M, Böll B, Hentrich M, Teschner D, Schalk E.. Scheduled removal of central venous catheters (CVC) to prevent CVC-related bloodstream infections in patients with hematological disease or autologous stem cell transplantation: a registry-based randomized simulation-study. *Ann Hematol*. 2022 Oct;101(10):2317-24. doi: 10.1007/s00277-022-04958-w. Epub 2022 Aug 17. PMID: 35978182
9. Wimmer T, Mattes R, Stemmler HJ, Hauck F, Schulze-Koops H, Stecher SS, Starck MW, Wendtner CM, Bojko P, Hentrich M, Nickel KE, Götze KS, Bassermann F, von Bergwelt-Baildon M, Spiekermann K. sCD25 as an independent adverse prognostic factor in adult HLH patients: results of a multicenter retrospective study. *Blood Adv*. 2022 Aug

16:bloodadvances.2022007953. doi: 10.1182/bloodadvances.2022007953. Online ahead of print. PMID: 35973195

10. Oette M, Hentrich M, Hoffmann C. HIV-assoziierte Neoplasien. *Best practice onkologie* 2022;17(4):142-9
11. Schalk E, Hentrich M. Real-World Data. *Dtsch Arztebl Int.* 2022 Feb 25;119(8):134. doi: 10.3238/arztebl.m2022.0035. PMID: 35506295
12. Dieckmann KP, Pokrivcak T, Geczi L, Niehaus D, Dralle-Filiz I, Matthies C, Dienes T, Zschäbitz S, Paffenholz P, Gschliesser T, Pichler R, Mego M, Bader P, Zengerling F, Heinzelbecker J, Krausewitz P, Krege S, Aurilio G, Aksoy C, Hentrich M, Seidel C, Törzsök P, Nestler T, Majewski M, Hiester A, Buchler T, Vallet S, Studentova H, Schönburg S, Niedersüß-Beke D, Ring J, Trenti E, Heidenreich A, Wülfing C, Isbarn H, Pichlmeier U, Pichler M. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. *Ther Adv Med Oncol.* 2022 Mar 31;14:17588359221086813. doi: 10.1177/17588359221086813. eCollection 2022. PMID: 35386956
13. Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). *World J Urol.* 2022 Feb;40(2):355-61. doi: 10.1007/s00345-021-03905-0. Epub 2022 Jan 7. PMID: 34993564
14. Schalk E, Hentrich M. Overweight or obesity are not risk factors for central venous catheter-related bloodstream infections in patients with hematological malignancies. *Infect Control Hosp Epidemiol.* 2021 Dec 20:1-3. doi: 10.1017/ice.2021.491. Online ahead of print. PMID: 34924070
15. Hentrich M. Multiple Myeloma: The Success Story Continues. *Oncol Res Treat.* 2021;44(12):659-61. doi: 10.1159/000520538. Epub 2021 Nov 15. PMID: 34781286
16. Hentrich M. HIV-assoziierte Lymphome. *InFo Hämatologie und Onkologie* 2021;24(11):17-21
17. Hentrich MU, Bower M, Daugaard G, Dieing A, Bickel M, Berretta M, Lesmeister F, Jurinovic V, Stoehr A, Heinzelbecker J, Krznicar I, Dieckmann KP, Necchi A, Maroto Rey P, Rockstroh JK, Brito M, Pfister D, Hoffmann C. Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. *Cancer.* 2022 Jan 15;128(2):260-8. doi: 10.1002/cncr.33928. Epub 2021 Sep 30. PMID: 34592009
18. Hentrich M, Oette M. 46/m mit zunehmendem analem Missempfinden und Pruritus. Vorbereitung auf die Facharztprüfung. Fall 11. *Onkologe(27)S1:S69-73*
19. Hentrich M. Diagnosis and treatment of HIV-associated lymphoma: Update 2021. *Dtsch Med Wochenschr.* 2021 Jun;146(11):e57. doi: 10.1055/a-1527-5585. Epub 2021 Jun 14. PMID: 34126644
20. Hentrich M, Müller M, Wyen C, Bogner J, Thomssen H, Wasmuth JC, Wolf T, Hoffmann C, Schommers P. Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. *Br J Haematol.* 2021 Aug;194(3):642-6. doi: 10.1111/bjh.17515. Epub 2021 May 7. PMID: 33959944
21. Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, et al.; International Germ Cell Cancer Classification Update Consortium. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. *J Clin Oncol.* 2021 May 10;39(14):1553-62. doi:

10.1200/JCO.20.03292. Epub 2021 Mar 17. PMID: 33729863

22. Gillessen S, Sauv  N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia-Del-Muro X, Heng DYC, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A, Hentrich M, et al.; International Germ Cell Cancer Classification Update Consortium. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. *J Clin Oncol.* 2021 May 10;39(14):1563-74. doi: 10.1200/JCO.20.03296. Epub 2021 Apr 6. PMID: 33822655
23. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, Hermanns T, Aparicio J, Heinzlbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C. The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). *World J Urol.* 2021 Sep;39(9):3407-14. doi: 10.1007/s00345-021-03635-3. Epub 2021 Mar 8. PMID: 33683412
24. H llein A, Bojko P, Schulz S, Neitz J, St tzer O, Pihusch R, Abedinpour F, Schmidt B, Hentrich M. Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study. *Acta Oncol.* 2021 Jan;60(1):24-7. doi: 10.1080/0284186X.2020.1863464. Epub 2021 Jan 5. PMID: 33397179
25. Christopheit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hentrich M, Karthaus M, Penack O, Ruhnke M, Weissinger F, Cornely OA, Maschmeyer G. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol.* 2021 Feb;100(2):321-6. doi: 10.1007/s00277-020-04297-8. Epub 2020 Oct 20. PMID: 33079221
26. Giesen N, Sprute R, R thrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, W rmann B, Cornely OA, K hler P, Schalk E, von Lilienfeld-Toal M. Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Eur J Cancer.* 2020 Nov;140:86-104. doi: 10.1016/j.ejca.2020.09.009. Epub 2020 Sep 21. PMID: 33068941
27. B ll B, Schalk E, Buchheidt D, Hasenkamp J, Kiehl M, Kiderlen TR, Kochanek M, Koldehoff M, Kostrewa P, Cla sen AY, Mellinghoff SC, Metzner B, Penack O, Ruhnke M, Vehreschild MJGT, Weissinger F, Wolf HH, Karthaus M, Hentrich M. *Ann Hematol.* 2021 Jan;100(1):239-59. doi: 10.1007/s00277-020-04286-x. Epub 2020 Sep 30. PMID: 32997191
28. Hentrich M, Debole J, Jurinovic V, Gerl A. Improved outcomes in metastatic germ cell cancer: results from a large cohort study. *Cancer Res Clin Oncol.* 2021 Feb;147(2):533-8. doi: 10.1007/s00432-020-03343-2. Epub 2020 Aug 9. PMID: 32772232
29. Hentrich M. Therapie von Hodentumoren. *InFo H matologie und Onkologie* 2020;23(11):48-56
30. Sch nermarck U, Hentrich M, Bassermann F, Theurich S, Fischereder M. Onconeurology - Interdisciplinary Cooperation of Nephrologists and Oncologists in the Treatment of Multiple Myeloma. *Dtsch Med Wochenschr.* 2020 Jun;145(12):828-35. PMID: 32557485

31. Ruhnke M, Cornely OA, Schmidt-Hieber M, Alakel N, Boell B, Buchheidt D, Christopeit M, Hasenkamp J, Heinz WJ, Hentrich M, Karthaus M, Koldehoff M, Maschmeyer G, Panse J, Penack O, Schleicher J, Teschner D, Ullmann AJ, Vehreschild M, von Lilienfeld-Toal M, Weissinger F, Schwartz S. Treatment of invasive fungal diseases in cancer patients - Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Mycoses*. 2020 Jul;63(7):653-82. doi: 10.1111/myc.13082. Epub 2020 May 12. PMID: 32236989
32. Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheeler M, Langberg CW, Ståhl O, Fankhauser CD, Hamid AA, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S; Global Germ-Cell Cancer Group. Outcome of men with relapses after adjuvant bleomycin, etoposide, and cisplatin for clinical stage I nonseminoma. *J Clin Oncol*. 2020 Apr 20;38(12):1322-31. doi: 10.1200/JCO.19.01876. Epub 2019 Dec 26. PMID: 31877087
33. Oing C, Hentrich M, Lorch A, Gläser D, Rumpold H, Ochsenreither S, Richter S, Dieing A, Zschäbitz S, Pereira RR, Bokemeyer C, Seidel C. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. *Cancer Res Clin Oncol*. 2020 Feb;146(2):449-55. doi: 10.1007/s00432-019-03071-2. Epub 2019 Dec 14. PMID: 31838576
34. Schalk E, Teschner D, Hentrich M, Böll B, Panse J, Schmidt-Hieber M, Vehreschild MJGT, Biehl LM. Central venous catheter-related bloodstream infections in patients with hematological malignancies: Comparison of data from a clinical registry and a randomized controlled trial. *Infect Control Hosp Epidemiol*. 2020 Feb;41(2):254-6. doi: 10.1017/ice.2019.335. PMID: 31818338
35. Grunwald VV, Hentrich M, Schiel X, Dufour A, Schneider S, Neusser M, Subklewe M, Fiegl M, Hiddemann W, Spiekermann K, Rothenberg-Thurley M, Metzeler KH. Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis. *Blood Adv*. 2019 Sep 24;3(18):2696-9. doi: 10.1182/bloodadvances.2019000265. PMID: 31515231
36. Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn-Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Oing C, Bokemeyer C. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). *Urol Oncol*. 2019 Nov;37(11):809.e19-809.e25. doi: 10.1016/j.urolonc.2019.07.020. Epub 2019 Sep 5. PMID: 31494007
37. Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. *Leukemia*. 2019 Nov;33(11):2710-9. doi: 10.1038/s41375-019-0537-2. Epub 2019 Aug 28. PMID: 31462732
38. Tölle D, Hentrich M, Pelzer BW, Kremer P, Einhell S, Schulz S, Böll B, Panse J, Schmidt-Hieber M, Teschner D, Schalk E. Impact of neutropenia on central venous catheter-related bloodstream infections in patients with hematological malignancies at the time of central venous catheter insertion: A matched-pair analysis. *Infect Control Hosp Epidemiol*. 2019 Oct;40(10):1204-6. doi: 10.1017/ice.2019.224. Epub 2019 Jul 29. PMID: 31352911
39. Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzlbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G. Serum Levels

of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. *J Clin Oncol*. 2019 Jun 1;37(16):1412-23. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15. PMID: 30875280.

40. Hübel K, Re A, Boumendil A, Finel H, Hentrich M, Robinson S, Wyen C, Michieli M, Kanfer E, Diez-Martin JL, Balsalobre P, Vincent L, Schroyens W, Santasusana JMR, Kröger N, Schiel X, Cwynarski K, Esquirol A, Sousa AB, Cattaneo C, Montoto S, Dreger P. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. *Bone Marrow Transplant*. 2019 Oct;54(10):1625-31. doi: 10.1038/s41409-019-0480-x. Epub 2019 Feb 25. PMID: 30804486.
41. Kochanek M, Schalk E, von Bergwelt-Baildon M, Beutel G, Buchheidt D, Hentrich M, Henze L, Kiehl M, Liebrechts T, von Lilienfeld-Toal M, Classen A, Mellinshoff S, Penack O, Piepel C, Böll B. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol*. 2019 May;98(5):1051-69. doi: 10.1007/s00277-019-03622-0. Epub 2019 Feb 22. PMID: 30796468
42. Fenner M, Oing C, Dieing A, Gauler T, Oechsle K, Lorch A, Hentrich M, Kopp HG, Bokemeyer C, Honecker F. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. *J Cancer Res Clin Oncol*. 2019 Mar;145(3):717-23. doi: 10.1007/s00432-018-2752-z. Epub 2018 Sep 19. PMID: 30232558
43. Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F, De Giorgi U, Fedyanin M, Oing C, Haugnes HS, Hentrich M, Fankhauser C, Gillissen S, Beyer J. Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. *J Clin Oncol*. 2018 Oct 4;JCO1800210. doi: 10.1200/JCO.18.00210. Online ahead of print. PMID: 30285559
44. Tritschler S, Erdelkamp R, Stief C, Hentrich M. Neuroendocrine prostate cancer. *Pathologe*. 2018 Jul;39(4):333-43. doi: 10.1007/s00292-018-0453-7. PMID: 29946852
45. Rieger CT, Liss B, Mellinshoff S, Buchheidt D, Cornely OA, Egerer G, Heinz WJ, Hentrich M, Maschmeyer G, Mayer K, Sandherr M, Silling G, Ullmann A, Vehreschild MJGT, von Lilienfeld-Toal M, Wolf HH, Lehnert N; (AGIHO). Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). *Ann Oncol*. 2018 Jun 1;29(6):1354-65. doi: 10.1093/annonc/mdy117. PMID: 29688266
46. Meister A, Hentrich M, Wyen C, Hübel K. Malignant lymphoma in the HIV-positive patient. *Eur J Haematol*. 2018 Jul;101(1):119-26. doi: 10.1111/ejh.13082. Epub 2018 May 22. PMID: 29663523
47. Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Bokemeyer C. Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors *Eur J Cancer*. 2018 May;94:16-25. doi: 10.1016/j.ejca.2018.01.113. Epub 2018 Mar 20. PMID: 29505967
48. Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, Zoufaly A, Wasmuth JC, Bogner JR, Müller M, Esser S, Schleicher A, Jensen B, Stoehr A, Behrens G, Schultze A, Siehl J, Thoden J, Taylor N, Hoffmann C. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. *Haematologica*. 2018 May;103(5):857-64. doi: 10.3324/haematol.2017.180893. Epub 2018 Feb 8. PMID: 29439188
49. Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT; AGIHO Working Group. Diagnosis and management of

gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol.* 2018 Jan;97(1):31-49. doi: 10.1007/s00277-017-3183-7. Epub 2017 Nov 24. PMID: 29177551

50. Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P. Nivolumab in HIV-related non-small-cell lung cancer. *Ann Oncol* 2017;28(11):2890. doi: 10.1093/annonc/mdx321. PMID: 29106466
51. Tritschler S, Erdelkamp R, Stief C, Hentrich M. Neuroendocrine prostate cancer. *Urologe A* 2017;56(11):1475-84. doi: 10.1007/s00120-017-0523-0. PMID: 29063171
52. Kiderlen TR, Siehl J, Hentrich M. HIV-associated malignant lymphoma. *Oncol Res Treat* 2017;40(3):88-92. doi: 10.1159/000458442. Epub 2017 Feb 20. PMID: 28259887
53. Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Hübel K. *Oncol Res Treat* 2017;40(3):82-7. doi: 10.1159/000456036. Epub 2017 Feb 24. PMID: 28253516
54. Hentrich M, Pfister D. HIV-Associated urogenital malignancies. *Oncol Res Treat* 2017;40(3):106-12. doi: 10.1159/000457130. Epub 2017 Feb 24. PMID: 28253510
55. von Lilienfeld-Toal M, Berger B, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf H-H, Lehnert N, Schalk E, Mayer K. Community acquired respiratory virus (CRV) infections in cancer patients - guideline on diagnosis and management by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). *Eur J Cancer* 2016;67:200-12
56. Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke G, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf H-H, Sezer O, Bargou R, Jung W, Trümper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schäfer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H, for the DSMM Study Group. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: Long-term outcome of a randomized trial. *Haematologica* 2016;101(11):1398-1406
57. Hausmann A, Fischer N, Breitkopf S, Menne F, Jess K, Schmidmayr S, Wendtner CM, Hentrich M. Severe motoric aphasia following reinfusion of cryopreserved autologous stem cells after myeloablative conditioning. *Transfusion* 2016;56(10):2615-7
58. Biehl LM, Huth A, Panse J, Krämer C, Hentrich M, Engelhardt M, Schäfer-Eckart K, Kofla G, Kiehl M, Wendtner CM, Karthaus M, Ullmann AJ, Hellmich M, Christ H, Vehreschild MJ. A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients. *Ann Oncol.* 2016;27(10):1916-22
59. Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel (GOP) in cisplatin-refractory germ cell cancer in routine care - Registry data from an outcomes research project of the German Testicular Cancer Study Group (GTCSG). *Urol Oncol* 2016;34(4):168.e21-8
60. Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Fätkenheuer G, Stier B, Wyen C, and Hentrich M. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or Non Hodgkin Lymphoma. *AIDS* 2016;30(5):753-60
61. Jokisch J-F, Ganswindt U, Hentrich M, Stief C, Karl A. Harnblasenkrebs. *MMW Fortschritte der Medizin* 2015;157:42-45

62. Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). *Ann Hematol* 2015;94(9):1441-50
63. Schommers P*, Hentrich M*, Hoffmann C, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Wolf T, Oette M, Müller M, Esser S, Vehreschild JJ, Fätkenheuer G, Wyen C. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. *Br J Haematol* 2015;168(6):806-10
64. Hoffmann C*, Hentrich M*, Gillor D, Behrens G, Jensen B, Stoehr A, Esser S, van Lunzen J, Krznaric I, Müller M, Oette M, Hensel M, Thoden J, Fätkenheuer G, Wyen C. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. *HIV Med* 2015;16(4):261-4
65. Straka C, Salwender H, Schnabel B, Sandherr M, Wandt H, Hübel K, Scheid C, Metzner B, Hentrich M, Franke D, Weidenegger G, Freund M, Sezer O, Einsele H, Hinke A, Emmerich B. Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. *Leuk Lymph* 2015;56(2):368-76
66. Morris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff GW, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kroger N, de Witte T, Ruutu T. Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. *Transfusion* 2014;54(10):2514-22
67. Hentrich M, Hoffmann C, Mosthaf F, Müller M, Siehl J, Wyen C, Hensel M. Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG). *Ann Hematol* 2014;93:913–921
68. Berger LA, Bokemeyer C, Lorch A, Hentrich M, Kopp HG, Gauler TC, Beyer J, de Wit M, Mayer F, Boehlke I, Oing C, Honecker F, Oechsle K. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). *J Cancer Res Clin Oncol* 2014;140(7):1211-20
69. Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth JC, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S, Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, Pérez M, Morgades M, González J, Fernández A, Thoden J, Gökbüget N, Hoelzer D, Fätkenheuer G, Wyen C. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. *Leuk Lymph* 2014;55(10):2341-8.
70. Fiegl M, Unterhalt M, Kern W, Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Schöndube D, Serve H, Reichle A, Hentrich M, Schiel X, Sauerland C, Heinecke A, Rieger C, Beelen D, Berdel WE, Büchner T, Hiddemann W. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. *Leukemia* 2014;28(5):1001-7.
71. Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology

(AGIHO). *Ann Hematol* 2014;93(7):1083-95

72. Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, Ruhnke M, Penack O, Salwender H, Wolf HH, Christopeit M, Neumann S, Maschmeyer G, Karthaus M. Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. *Ann Oncol* 2014;25(5):936-47.
73. Gerl A, Hentrich M. Aktuelle Therapie- und Nachsorgestrategien bei Hodentumoren. *InFo Onkologie* 2014;4:38-45.
74. Re A, Cattaneo C, Skert C, Balsalobre P, Michieli M, Bower M, Ferreri AJ, Hentrich M, Ribera JM, Allione B, Schommers P, Montoto S, Almici C, Ferremi P, Mazzucato M, Gattillo S, Casari S, Spina M, Diez-Martin JL, Tirelli U, Rossi G. Stem cell mobilization in HIV seropositive patients with lymphoma. *Haematologica* 2013;98(11):1762-8.
75. Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Fätkenheuer G, Hoffmann C. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. *AIDS* 2013;27:842-5
76. Fegg MJ, Brandstätter M, Kögler M, Hauke G, Rechenberg-Winter P, Fensterer V, Küchenhoff H, Hentrich M, Belka C, Borasio GD. Existential behavioural therapy for informal caregivers of palliative patients: a randomised controlled trial. *Psychooncology* 2013;22:2079-86
77. Vehreschild MJ, Vehreschild JJ, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, Maschmeyer G, Schalk E, Cornely OA, Neumann S. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Oncol* 2013;24:1189-202
78. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schwyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. *Ann Oncol* 2013;24:878-8
79. Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. *J Clin Oncol* 2012;30:4117-23
80. Hentrich M, Gerl A. Primärtherapie von Keimzelltumoren des Hodens. *Krebsmedizin* 2012;21(2):62-74
81. Gerl A, Hentrich M. Nachsorge von Patienten mit Hodentumoren. *Krebsmedizin* 2012;21(2):75-82
82. Wyen C, Jensen B, Hentrich M, Siehl S, Sabranski M, Esser S, Gillor D, Müller M, van Lunzen J, Wolf T, Bogner J, Wasmuth JC, Thoden J, Christ H, Fätkenheuer G, Hoffmann C. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. *AIDS* 2012;26:457-464

83. Scherberich JE, Kornmeier A, Wiemer J, Hentrich M, Kremer M, Amann K. Nephrotisches Syndrom, Niereninsuffizienz und Raumforderungen in Leber und Milz. *Nephrologe* 2012;7:423-7
84. Rölling C, Brandts C, Shaid S, Hentrich M, Krämer A, Junghanß C, Schleyer E, Müller-Tidow C, Berdel WE, Ritter B, Pflüger KH, Kramer M, Haibach M, Ehninger G, Serve H, Krause S. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. *Leuk Lymph* 2012;53:1062-7
85. Straka C, Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hübel K, Silling G, Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger G, Grimminger W, Engert A, Schlimok G, Scheid C, Hellmann P, Heinisch H, Einsele H, Hinke A, Emmerich B. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. *Blood* 2011;117:2121-8
86. Karthaus M, Hentrich M. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis. *Mycoses* 2011;54 Suppl 1:1-6
87. Penack O, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, Salwender H, Wolf HH, Ostermann H. Management of sepsis in neutropenic patients: guidelines of the infectious diseases working party of the German Society of Hematology and Oncology. *Ann Oncol* 2011;22:1019-29
88. Hentrich M, Mosthaf F. Maligne Lymphome bei HIV-Infektion. *InFoOnkologie* 2010;13:46-52
89. Hentrich M, Schiel X, Niedermeier A, Lutz L, Rupec R, Stief C, Bogner J, Karthaus M, Gerl A. Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor. [Ann Oncol](#). 2009;20:1900-1
90. Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Buchner T, Hiddemann W. Dose-dense induction with sequential-high-dose cytarabine and mitoxantrone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de-novo acute myeloid leukaemia – a pilot study of the AML-CG. *Blood* 2009;113:3903-10
91. Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera J, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A. Comparable survival between HIV positive and HIV negative non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell Transplantation. *Blood* 2009;113:6011-4
92. Schlemmer M, Kühl M, Schalhorn A, Rauch J, Jauch K-W, Hentrich M. Tissue levels of 5,10 methylenetetrahydrofolate and tetrahydrofolate in patients with colorectal carcinoma following Infusion of folinic acid at various dose levels. *Clin Cancer Res* 2008;14:7930-4
93. Hentrich M, Schiel X, Scheidt B, Reitmeier M, Lutz L. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer. *Acta Oncol* 2008;47:155-6
94. Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J, Ledderose G, Oruzio D, Hiddemann W, Kolb H-J. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. *Bone Marrow Transplant* 2008;41:721-7
95. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Röthling N, Peschel C, Lordick F. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in

advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. *Ann Oncol* 2007;18:1673-9

96. Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf H-H, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. *Br J Haematol* 2007;138:330-7
97. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Übelacker R, Buchheidt D, Behre G, Hiddemann W, Schiel X. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multi-center trial. *Crit Care Med* 2006;34:1319-25
98. Hentrich M, Marettta L, Chow KU, Bogner J, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiß R, Rockstroh J, Arasteh K, Mitrou P. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. *Ann Oncol* 2006;17:914-9 sowie *Ann Oncol SA Excerpts Edition* 2006;3:249-54
99. Schiel X, Link H, Maschmeyer G, Glaß B, Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Ostermann W, Hentrich M, for the Study Group of the Paul-Ehrlich-Society. A prospective, randomized multicenter trial of a sequential empirical antibiotic and antifungal therapy for febrile neutropenic cancer patients: Results of the Paul-Ehrlich-Society for Chemotherapy (PEG) Multicenter Trial II. *Infection* 2006;34:118-126
100. Weiß R, Mitrou P, Arastéh K, Schuermann D, Hentrich M, Duehrsen U, Sudeck H, Schmidt-Wolf IG, Anagnostopoulos I, Huhn D. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is save and improves survival - Results of the German Multicenter Trial. *Cancer* 2006;106:1560-8
101. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, van Lunzen J, Stellbrink H-J, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst H-A. Aids-associated Burkitt- or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. *Leuk Lymph* 2006;47:1872-80
102. Hentrich M, Fegg M, Jost Ch, Meiler S, Gerl A. Smoking Cessation in Long-Term Survivors of Germ Cell Tumor (GCT). *J Cancer Res Clin Oncol* 2006;132:557-60
103. Schlemmer M, Wendtner C-M, Falk M, Licht T, Abdel-Rahman S, Baumert J, Straka C, Hentrich M, Salat C, Hiddeman W, Issels RD. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral stem cell rescue (PBSCR) in chemosensitive patients with metastatic soft tissue sarcomas. *Oncology* 2006;71:32-9
104. Reimer P, Hentrich M. Peripheral T-cell lymphoma: diagnosis and treatment. *Dtsch Med Wochenschr* 2006;131:685-90 sowie *Pharma Fokus Onkologie* 2006;3(1):13-19
105. Hentrich M, Oruzio D, Jäger G, Schlemmer M, Schleuning M, Schiel X, Hiddemann W, Kolb HJ. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. *Br J Haematol* 2005;128:66-72
106. Hentrich M, Weber N, Bergsdorf T, Bernhard Liedl B, Hartenstein R, Gerl A. Management and Outcome of Bilateral Testicular Germ Cell Tumors: 25 year experience in Munich. *Acta Oncol* 2005;44:529-36
107. Ballova V, Ruffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HAT, Josting A, Löffler M, Diehl V,

Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). *Ann Oncol* 2005;16:124-31

108. Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. *Br J Cancer* 2005;93:190-4
109. Lordick F, Hentrich M, Decker T, Hennig M, Pohlmann H, Hartenstein R, Peschel C. Ultrasound screening for internal jugular vein thrombosis aids the detect of central venous catheter-related infections in patients with haematological diseases: a prospective observational study. *Br J Haematol* 2003;120:1073-8
110. Kropff MH, Lang N, Bisping G, Domine N, Innig G, Hentrich M, Mitterer M, Sudhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. *Br J Haematol* 2003;122:607-16
111. Bittmann I, Hentrich M, Bise K, Kolb HJ, Löhrs U. Endothelial cells but not epithelial cells or cardiomyocytes are partially replaced by donor cells after allogeneic bone marrow and stem cell transplantation. *J Hematother Stem Cell Res* 2003;12:359-66
112. Pihusch R, Salat C, Göhring P, Hentrich M, Wegner H, Pihusch M, Hiller E, Kolb HJ, Ostermann H. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut. *Br J Haematol* 2002;117:469-76
113. Kollmannsberger C, Rick O, Klaproth H, Kubin T, Sayer H, Hentrich M, Welslau M, Mayer F, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: A phase II study of the German Testicular Cancer Study Group. *Br J Cancer* 2002;87:729-32
114. Hentrich M, Stötzer OJ, Salat C, Ledderose G. Chronic myeloid leukemia – case report. *Dtsch Med Wochenschr* 2002;127:2617
115. Stötzer OJ, Hentrich M, Salat C. Chronic myeloid leukemia – pathophysiology and diagnosis. *Dtsch Med Wochenschr* 2002;127:2618-20
116. Stötzer OJ, Hentrich M, Salat C. Chronic myeloid leukemia – treatment. *Dtsch Med Wochenschr* 2002;127:2621-4
117. Munker R, Brack N, Hentrich M, Kolb HJ. Transplantation von Blutstammzellen heute. Indikationen, Komplikationen und aktuelle Entwicklungen. *Kliniker* 2001;7/8:218-25
118. Hentrich M, Rockstroh J, Sandner R, Brack N, Hartenstein R. Acute myelogenous leukaemia and myelomonocytic blast crisis following polycytemia vera in HIV positive patients: report of cases and review of the literature. *Ann Oncol* 2000;11:195-200
119. Hentrich M, Jäger H, Hartenstein R. HIV-assoziierte Malignome. *Onkologie* 1999;22:240-4
120. Hentrich M, Hartenstein R. Behandlung maligner Körperhöhlenergüsse. *Internist* 1997;8:794-804 sowie *Onkologie* 1997;3:163-73
121. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. *Ann Oncol* 1997;8:41-7

122. Hentrich M, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein R. Testicular germ cell tumors in patients with human immunodeficiency virus infection. *Cancer* 1996;77:2109-16
123. Hentrich M, Meister P, Brack NG, Lutz L, Hartenstein R. Adult Wilms` tumor. Report of two cases and review of the literature. *Cancer* 1995;75:545-51
124. Hentrich M, Hartenstein R. Wilms` tumor in adults. *Onkologie* 1995;18:310-5
125. Gerl A, Clemm C, Hentrich M, Hartenstein R, Wilmanns W. Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first line chemotherapy for poor-risk non-seminomatous germ cell tumors. *Acta Oncol* 1993;32:541-6
126. Meister P, Nerl C, Pickl-Pfeffer S, Brack N, Hentrich M, Pohlmann H, Horn J. Pilzsepsis bei unreifzelliger Leukämie. *MMW* 1993;135(47):647-50
127. Peikert A, Hentrich M, Ochs G. Topical 0,025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. *J Neurol* 1991;238:452-6